###begin article-title 0
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
Analysis of Nigerians with Apparently Sporadic Parkinson Disease for Mutations in LRRK2, PRKN and ATXN3
###end article-title 0
###begin p 1
Conceived and designed the experiments: NO RA JH AS JB. Performed the experiments: AB JB. Analyzed the data: AB AS JB. Contributed reagents/materials/analysis tools: NO CC RA. Wrote the paper: NO JH AS JB.
###end p 1
###begin p 2
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 451 456 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 461 466 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
Several genetic variations have been associated with Parkinson disease in different populations over the past few years. Although a considerable number of worldwide populations have been screened for these variants, results from Sub-Saharan populations are very scarce in the literature. In the present report we have screened a cohort of Parkinson disease patients (n = 57) and healthy controls (n = 51) from Nigeria for mutations in the genes PRKN, LRRK2 and ATXN3. No pathogenic mutations were found in any of the genes. Hence, common pathogenic mutations in these genes, observed in several different populations, are not a frequent cause of Parkinson disease in Nigeria.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 446 449 442 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Polymeropoulos1">[1]</xref>
###xml 504 509 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 531 534 527 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-PaisanRuiz1">[2]</xref>
###xml 536 539 532 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Zimprich1">[3]</xref>
###xml 661 664 657 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Kitada1">[4]</xref>
###xml 736 739 732 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Valente1">[5]</xref>
###xml 795 798 791 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Bonifati1">[6]</xref>
###xml 883 888 879 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 903 906 899 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-GwinnHardy1">[7]</xref>
###xml 941 944 937 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-GwinnHardy2">[8]</xref>
The identification of monogenic causes of Parkinson's disease (PD) (MIM #168600) has improved our understanding of the pathogenesis of the disease and promises to facilitate the development of biomarkers to aid early diagnosis and interventions that may slow disease progression or even provide a cure in the future. Mutations in two genes have been linked to autosomal dominant PD; the first, encoding alpha-synuclein (SNCA; MIM #163890; PARK1) [1] and the second encoding leucine-rich repeat kinase 2 (LRRK2; MIM #609007; PARK8) [2], [3]. Mutations in three genes have been linked to autosomal recessive PD: the gene encoding parkin (PRKN; MIM #602544; PARK2)[4], the gene encoding PTEN - induced kinase 1 (PINK1; MIM #608309; PARK6) [5] and the gene encoding DJ-1 (PARK7; MIM #602533; PARK7) [6]. In addition, pathogenic repeat expansion mutations in the genes encoding ataxin-3 (ATXN3; MIM #109150) [7] and ataxin-2 (ATXN2; MIM #183090) [8] have been described as autosomal dominant causes of PD.
###end p 4
###begin p 5
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 367 370 367 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Bras1">[9]</xref>
###xml 402 406 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Lesage1">[10]</xref>
###xml 417 422 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 618 622 618 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Shimura1">[14]</xref>
###xml 637 641 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 738 742 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Lucking1">[11]</xref>
###xml 814 818 814 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 902 906 902 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Lucking2">[12]</xref>
###xml 908 912 908 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Lincoln1">[13]</xref>
###xml 965 969 965 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 1065 1069 1065 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 1310 1314 1310 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Chung1">[15]</xref>
###xml 1343 1347 1343 1347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 1471 1475 1471 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Lincoln1">[13]</xref>
###xml 1592 1596 1592 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 1668 1672 1668 1672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Klein1">[16]</xref>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 1554 1561 <span type="species:ncbi:9606">patient</span>
The frequency of mutations and the risk attributable to polymorphisms in LRRK2, PRKN and ATXN3 in patients with sporadic PD has been explored in several studies. Mutations in LRRK2, specifically G2019S, appear to be the most common known genetic lesion underlying PD (including the apparently sporadic form), with frequencies as high as 6% in the European population [9] and 41% in North African Arabs [10]. The gene LRRK2 on chromosome 12q12 encodes a primarily cytoplasmic protein kinase, the function of which has not been clearly elucidated. Parkin is a ubiquitin-protein ligase that maps to chromosome 6q25.2-q27 [14]. Mutations in PRKN have been reported as the most frequent cause of autosomal recessive juvenile onset familial PD [11]. However, studies investigating the role of genetic variability at the PRKN locus in determining susceptibility to sporadic PD have provided differing results [12], [13]. A wide variety of mutations have been described in PRKN, ranging from point mutations to whole exon duplications and deletions. The mechanism by which PRKN mutations exert a pathogenic effect is not fully understood, but may involve loss of function and inhibition of parkin's ubiquitin E3 ligase activity and consequent enhancement of neurodegeneration via impaired ubiquitination of substrates [15]. In considering the role of PRKN variants in PD, two main notions should be considered. First, heterozygous mutations are fairly common in healthy subjects [13], and second, the presence of an apparent single heterozygous mutation in a PD patient typically should not rule out PRKN as the causative gene, since other unscreened mutations may be present [16].
###end p 5
###begin p 6
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 234 239 234 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 392 395 392 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-GwinnHardy1">[7]</xref>
###xml 416 421 416 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 682 686 682 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Subramony1">[17]</xref>
Machado-Joseph disease (MJD/ATXN3) is an autosomal dominant progressive neurologic disorder characterized primarily by ataxia, spasticity, and ocular movement abnormalities. The disease is caused by a CAG repeat expansion in the gene ATXN3. In 2001, Gwinn-Hardy and colleagues reported a family of sub-Saharan African descent with several individuals displaying parkinsonism suggestive of PD [7]. In this family the ATXN3 mutation segregated completely with the suggestive PD phenotype. Several cases of PD caused by repeat expansion mutation have been described in African-Americans, and it has been suggested that genetic background may modulate the expressivity of this mutation [17].
###end p 6
###begin p 7
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Okubadejo1">[18]</xref>
###xml 679 684 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 686 690 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 695 700 695 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
In spite of the upsurge in research and publications relating to PD genetics in the past decade, much less is known about the genetics of PD in the African subcontinent, with the majority of publications to date focusing on the North African population [18]. Understanding the genetic associations of PD in Africans will improve our understanding of disease pathogenesis, and improve decision making relating to the usefulness of commercially available predictive genetic tests and preventive and therapeutic interventions that may become available in the future. This study reports the preliminary data from the screening of apparently sporadic cases of PD from West Africa for LRRK2, PRKN and ATXN3 mutations.
###end p 7
###begin title 8
Methods
###end title 8
###begin title 9
Population
###end title 9
###begin p 10
###xml 1632 1636 1632 1636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-1">[19]</xref>
###xml 1661 1665 1661 1665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Hoehn1">[20]</xref>
###xml 1712 1716 1712 1716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Folstein1">[21]</xref>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
###xml 481 489 <span type="species:ncbi:9606">patients</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
###xml 590 598 <span type="species:ncbi:9606">patients</span>
###xml 700 708 <span type="species:ncbi:9606">patients</span>
###xml 895 903 <span type="species:ncbi:405018">cardinal</span>
###xml 1217 1225 <span type="species:ncbi:9606">patients</span>
The study protocol was approved by the Research and Ethics Committee of the Lagos University Teaching Hospital, Lagos, Nigeria. Written informed consent was obtained from all patients and controls. Using a case-control design, 57 unrelated black African PD patients (43 males and 14 females) aged 43 to 80 years and 51 age-matched healthy individuals without a family history of PD or tremor (35 males and 16 females; age range 42 to 87) were recruited from sequentially attending patients at the Neurology Out-patients clinic of the Lagos University Teaching Hospital, Lagos, Nigeria. All patients were evaluated by a neurologist specializing in movement disorders, with keen attention to excluding patients with a possible secondary etiology. The PD cases recruited were those with clinically definite PD only. The inclusion criteria were the presence of all five of: a) at least two of three cardinal signs of tremor, rigidity, bradykinesia (with or without postural or gait abnormality); b) an asymmetric onset; c) no identifiable secondary cause (e.g. repeated stroke, exposure to medications capable of causing PD within 6 months before onset, etc); d) responsiveness to levodopa therapy (applicable to treated patients only); e) absence of signs of more extensive nervous system involvement (e.g. early autonomic features or cognitive impairment within 2 years of onset, otherwise unexplained corticospinal tract dysfunction, and cerebellar signs). All PD cases were evaluated using a standard protocol that included a historical account, neurological examination, Unified Parkinson's Disease Rating Scale (UPDRS) assessment [19], Hoehn and Yahr staging [20], and Folstein's Mini Mental State examination [21]. Control subjects had an abridged neurologic examination to exclude parkinsonism, cognitive impairment, corticospinal tract dysfunction, or any overt neurologic illness. Saliva samples were collected from each case and control using the Oragene kit (DNA Genotek).
###end p 10
###begin p 11
###xml 565 569 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNCA</italic>
###xml 32 39 <span type="species:ncbi:9606">patient</span>
###xml 95 103 <span type="species:ncbi:405018">cardinal</span>
###xml 185 193 <span type="species:ncbi:9606">patients</span>
The mean age at onset (based on patient's or caregiver's recollection of age at onset of first cardinal symptom of PD) for this group is 58.2+/-9.1 years (range 40-75). The majority of patients presented no apparent family history for parkinsonism, while nine presented at least one first-degree relative with a history of tremors. This fact may suggest that, for these nine individuals, an autosomal dominant mode of inheritance is possible. Hence, this study will fail to rule out the possibility of mutations in one of the known autosomal dominant PD genes, the SNCA gene.
###end p 11
###begin p 12
###xml 13 21 <span type="species:ncbi:9606">patients</span>
Although all patients are from Nigeria, their specific ethnic origins were as follows: Yoruba - 35 (61.4%), Igbo - 11 (19.3%), and Edo (Ijaw/ Itsekiri/ Urhobo/ other south-south ethnicity) - 11 (19.3%). The ethnic origins of the controls were as follows: Yoruba - 36 (70.6%), Igbo - 9 (17.6%), Edo - 5 (9.8%) and Hausa - 1 (2%).
###end p 12
###begin p 13
###xml 55 62 55 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003421-t001">Table 1</xref>
Further details of cases and controls are presented in Table 1.
###end p 13
###begin title 14
Clinical characteristics of PD cases and controls
###end title 14
###begin p 15
Levodopa responsiveness not applicable in 3 of the 57 who were pre-treatment cases.
###end p 15
###begin title 16
Analysis of mutations
###end title 16
###begin p 17
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 348 351 348 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Kitada1">[4]</xref>
###xml 353 357 353 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 483 488 483 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 606 609 606 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Bras1">[9]</xref>
###xml 611 616 611 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 719 723 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Subramony1">[17]</xref>
Genomic DNA was extracted from saliva using the Oragene kit (DNA Genotek). PRKN, LRRK2 and ATXN3 were screened for mutations. For PRKN, all exons and intron/exon boundaries were polymerase chain reaction-amplified and sequenced in both directions using BigDye chemistry (Applied Biosystems, Foster City, CA) on an ABI3730xl as previously described [4]. PRKN mutations are numbered according to GenBank accession number NP_004553 for the protein (p.) and NM_004562 for the cDNA (c.). LRRK2 was screened by sequence analysis for the most common mutations occurring in exons 31 and 41 as previously described [9]. ATXN3 pathogenic repeat expansion size was assessed in all samples using methods described previously by us [17].
###end p 17
###begin title 18
Copy number analysis
###end title 18
###begin p 19
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-SimonSanchez1">[22]</xref>
###xml 1128 1132 1128 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 1132 1136 1132 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-SimonSanchez1">[22]</xref>
###xml 505 510 <span type="species:ncbi:9606">Human</span>
In addition to sequencing PRKN, we screened PRKN for copy number mutations in two samples carrying heterozygous mutations not found in controls (p.P153R; c.C458G and p.R334H; c.G1001A), using the Illumina Infinium HumanHap550 BeadChips (version 3; Illumina Inc, San Diego, CA, USA) as previously described [22]. Copy number analysis by genotyping was done according to the manufacturer's protocol (Illumina Inc.) using 750 ng of genomic DNA. Data was analysed with BeadStudio v3 (Illumina Inc.) using the Human Genome build 35. Two metrics were visualized using this tool, B allele frequency and log R ratio. The former is the theta value for an individual SNP, which gives an estimate of the proportion of times an individual allele at each polymorphism is called A or B. The log R ratio is the log2 ratio of the observed normalized R value for the SNP divided by the expected normalized R value for the SNPs theta value. An R above 1 is indicative of an increase in copy number, and values below 1 suggest a deletion. We have shown previously that this is a reliable method for detecting large genomic copy number mutation in PRKN[22].
###end p 19
###begin title 20
Results
###end title 20
###begin p 21
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 359 363 359 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 386 393 386 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003421-t002">Table 2</xref>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
We did not find any variants in exons 31 and 41 of LRRK2. Likewise, the screening for the ATXN3 repeats revealed that no samples contained pathogenic expansions. The PRKN gene yielded several variants, some new and others previously described. With the exception of the V380L and S167N polymorphisms, no other missense homozygous variants were found. All the PRKN variants are shown in Table 2. Additionally, samples that showed only one heterozygous mutation in PRKN that was not present in controls were screened for copy number variants in this gene, in order to assess if these were in fact compound heterozygous for one point and one genomic copy number mutation. Genomic copy number analysis did not detect any mutations in these samples.
###end p 21
###begin title 22
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PARK2</italic>
PARK2 gene variants in PD cases and controls
###end title 22
###begin title 23
Discussion
###end title 23
###begin p 24
###xml 224 232 <span type="species:ncbi:9606">patients</span>
This is the first study screening a sub-Saharan African cohort of apparently sporadic PD cases for mutations in genes commonly associated with PD. The results from this study are of clear importance not only for Nigerian PD patients, but also because they shed light on the genetic background associated with PD in the African population. It should be noted that the number of individuals included in this preliminary report is clearly small, and thus, definite conclusions about frequencies of variants are difficult to achieve.
###end p 24
###begin p 25
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 121 125 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 190 195 190 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PINK1</italic>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DJ-1</italic>
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN2</italic>
###xml 318 322 318 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNCA</italic>
###xml 560 564 560 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNCA</italic>
###xml 624 629 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 933 937 933 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Lesage1">[10]</xref>
###xml 1024 1029 1024 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 1180 1185 1180 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 1247 1252 1247 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 1391 1396 1391 1396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 1457 1461 1457 1461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-PaisanRuiz2">[23]</xref>
###xml 1919 1923 1919 1923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Lesage2">[24]</xref>
###xml 1925 1929 1925 1929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Kachergus1">[25]</xref>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 1801 1806 <span type="species:ncbi:9606">human</span>
We have performed a screening for the most common autosomal recessive variants in three genes associated with PD (LRRK2, PRKN and ATXN3). We decided not to screen for mutations in the genes PINK1, DJ-1 and ATXN2 given the low frequency of mutations in these genes in worldwide populations. Moreover, we did not screen SNCA as mutations in this gene are not only rare but they are also associated with an autosomal dominant mode of inheritance. Given that the majority of our patients have no affected family members with any form of parkinsonism, mutations in SNCA would be unlikely to occur in our cohort. Mutations in the LRRK2 are the most common cause of PD in several populations, including populations of Northern-African ancestry. In particular, Lesage and colleagues found a high frequency (41%) of the G2019S mutation on exon 41 in a study of North African Arabs that included both familial and apparently sporadic PD cases [10]. Thus, it would be interesting to determine if there is a similarly high frequency of LRRK2 G2019S mutations in other geographically and ethnically distinct parts of Africa. However, we did not find any mutations in either exons 31 and 41 of LRRK2 in our cohort, suggesting that mutations in these domains of LRRK2 are not a common cause of PD in sub-Saharan populations. A recent study performed a comprehensive analysis of the entire coding region of LRRK2 in a large cohort of American PD cases and healthy controls [23]. Of the seven mutations found to be segregating with disease, five were in either exon 31 or exon 41, indicating these as clear mutational hotspots. The noteworthy difference in mutation frequency among populations from the same continent is, in all probability, due to the occurrence of the founding G2019S mutation event happening after human populations moved out of sub-Saharan Africa as this is most consistent with the dating of this mutational event [24], [25].
###end p 25
###begin p 26
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATXN3</italic>
Parkinsonism due to ATXN3 repeat expansion mutation has been previously described in one single large African descent family. We failed to find any samples harboring the increased repeat expansion size. This result suggests that ATXN3 repeat expansion mutations are not a frequent cause of parkinsonism in this population.
###end p 26
###begin p 27
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 346 350 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 628 632 628 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Ng1">[26]</xref>
###xml 1488 1492 1488 1492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Lucking2">[12]</xref>
###xml 1494 1498 1494 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003421-Lincoln1">[13]</xref>
###xml 371 379 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
Even though a considerable number of PRKN mutations are dosage mutations, the majority are sequence variants, hence, we decided to perform the initial screen of our cohort only for these variants. Subsequently, we performed gene dosage analysis in two samples as previously detailed. Again, our study did not identify any pathogenic mutations in PRKN in our subset of PD patients. We found several heterozygous variants both in patients and controls.,Two of the variants are novel and present only in PD cases (p.R334H and p.A46T). Given the fact that these are novel variants, we ran the analysis software SIFT (available at ) [26] in order to have some insight into the potential effects of these variants. The p.A46T was predicted by the software to potentially affect protein function, whereas the p.R334H was predicted to have no functional effect. However, these results are merely based on a similarity score in comparison to other proteins, and hence it must be stressed that this is not true functional data for these variants. Nonetheless, in the absence of a second mutation, these cannot be described as pathogenic, thus we decided to classify these as variants of unknown pathogenicity. It should be noted that for these two samples, an additional screen for gene dosage mutations was performed using the Illumina BeadChips. In addition, one homozygous variant was found only in the PD group (p.S167N; c.G500A). However, this has previously been classified as a polymorphism [12], [13].
###end p 27
###begin p 28
All populations showed polymorphisms with varying frequencies. Three variants p.A46T, p.P153R and p.R334H were found in a single sample each. Variant p.A46T was present in one PD sample from Igbo, p.P153R was found in a Yoruban sample, and p.R334H was present in a sample with Edo background. Two individuals, both from the same ethnic region (Edo), presented with two missense variants each (p.M129L and p.S167N; p.M129L and p.V380L). Although the present study cannot completely rule out that these compound hetererozygous events could potentially be pathogenic, two facts suggest otherwise: 1) in each case the second variant is a well known and described SNP; 2) one control sample presented the same combination of two of the variants (p.M129L and p.V380L).
###end p 28
###begin p 29
###xml 499 503 499 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 570 575 570 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 867 872 867 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 973 977 973 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 1023 1027 1023 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRKN</italic>
###xml 931 939 <span type="species:ncbi:9606">patients</span>
We report the first genetic screening for PD genes in a sub-Saharan population. We found no pathogenic mutations in the genes most commonly known to cause PD in European North American, or North African populations. Although the cohort studied is clearly small and definite conclusions regarding frequencies are unachievable, a trend for different genetic basis of PD in this sub-Saharan population is, in our opinion, noteworthy. Two main caveats are present in this work: gene dosage mutations in PRKN were only screened for in two samples and only exons 31 and 41 of LRRK2 were sequenced. Nevertheless, the aim of this study was to ascertain a preliminary frequency of the most common variants known to cause PD in a sub-Saharan population. We report here that the most common variant associated with PD in several world-wide populations, the p.G2019S mutation in LRRK2, is not overrepresented in this Nigerian population of PD patients; similarly, sequence variants in PRKN, which represent a significant proportion of PRKN mutations underlying PD, are also not significantly present in the studied cohort. It is thus likely that the differences in the genetic background of these populations mean that other genes or different variants are underlying the disease. Therefore, a search for these is clearly warranted, since they will, in all probability, shed more light on different pathways leading to PD.
###end p 29
###begin title 30
References
###end title 30
###begin article-title 31
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
###end article-title 31
###begin article-title 32
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.
###end article-title 32
###begin article-title 33
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
###end article-title 33
###begin article-title 34
Mutations in the parkin gene cause autossomal recessive juvenile parkinsonism.
###end article-title 34
###begin article-title 35
Hereditary early-onset Parkinson's disease caused by mutations in PINK1.
###end article-title 35
###begin article-title 36
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.
###end article-title 36
###begin article-title 37
Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family.
###end article-title 37
###begin article-title 38
Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese.
###end article-title 38
###begin article-title 39
G2019S Dardarin Substitution is a Common Cause of Parkinson's Disease in a Portuguese Cohort.
###end article-title 39
###begin article-title 40
LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs.
###end article-title 40
###begin article-title 41
Association between earlyonset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group.
###end article-title 41
###begin article-title 42
Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease.
###end article-title 42
###begin article-title 43
Parkin variants in North American Parkinson's disease: cases and controls.
###end article-title 43
###begin article-title 44
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.
###end article-title 44
###begin article-title 45
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function.
###end article-title 45
###begin article-title 46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism.
###end article-title 46
###begin article-title 47
Ethnic differences in the expression of neurodegenerative disease: Machado-Joseph disease in Africans and Caucasians.
###end article-title 47
###begin article-title 48
An analysis of genetic studies of Parkinson's disease in Africa.
###end article-title 48
###begin article-title 49
The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations.
###end article-title 49
###begin article-title 50
Parkinsonism: onset, progression, and mortality. 1967.
###end article-title 50
###begin article-title 51
###xml 75 83 <span type="species:ncbi:9606">patients</span>
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
###end article-title 51
###begin article-title 52
Genomewide SNP assay reveals mutations underlying Parkinson disease.
###end article-title 52
###begin article-title 53
Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls.
###end article-title 53
###begin article-title 54
LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century.
###end article-title 54
###begin article-title 55
Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations.
###end article-title 55
###begin article-title 56
###xml 15 20 <span type="species:ncbi:9606">human</span>
Accounting for human polymorphisms predicted to affect protein function.
###end article-title 56
###begin p 57
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 57
###begin p 58
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 172 177 <span type="species:ncbi:9606">Human</span>
Funding: This research was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services; Annual Report number Z01-AG000957-05 and Portuguese FCT grant #SFRH/BD/29647/2006.
###end p 58

